Cargando…
KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer
PARP inhibitors (PARPi) are currently used as first-line therapy for advanced and recurrent ovarian cancer, but the clinical efficacy is limited by drug resistance. We aimed to investigate the role of KIAA1529 in PARPi resistance in ovarian cancer. The expression of KIAA1529 was determined in ovaria...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352548/ https://www.ncbi.nlm.nih.gov/pubmed/35917645 http://dx.doi.org/10.1016/j.tranon.2022.101497 |